Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bacterial Infections and Mycoses

  Free Subscription


Articles published in J Antimicrob Chemother

Retrieve available abstracts of 230 articles:
HTML format
Text format



Single Articles


    June 2018
  1. TAVERNIER S, Sass A, De Bruyne M, Baeke F, et al
    Decreased susceptibility of Streptococcus anginosus to vancomycin in a multispecies biofilm is due to increased thickness of the cell wall.
    J Antimicrob Chemother. 2018 Jun 12. pii: 5036452. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. BOUDJEMAA R, Steenkeste K, Jacqueline C, Briandet R, et al
    Live intramacrophagic Staphylococcus aureus as a potential cause of antibiotic therapy failure: observations in an in vivo mouse model of prosthetic vascular material infections.
    J Antimicrob Chemother. 2018 Jun 12. pii: 5036450. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. DESHPANDE LM, Castanheira M, Flamm RK, Mendes RE, et al
    Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program.
    J Antimicrob Chemother. 2018 Jun 6. pii: 5033815. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2018
  4. TALBOT JJ, Subedi S, Halliday CL, Hibbs DE, et al
    Surveillance for azole resistance in clinical and environmental isolates of Aspergillus fumigatus in Australia and cyp51A homology modelling of azole-resistant isolates.
    J Antimicrob Chemother. 2018 May 29. pii: 5018389. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. ARENDRUP MC, Verweij PE, Mouton JW, Lagrou K, et al
    Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus.
    J Antimicrob Chemother. 2018 May 25. pii: 5003466. doi: 10.1093.
    PubMed     Text format    


  6. BREAK TJ, Desai JV, Healey KR, Natarajan M, et al
    VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice.
    J Antimicrob Chemother. 2018 May 16. pii: 4996888. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  7. SEUFERT R, Sedlacek L, Kahl B, Hogardt M, et al
    Prevalence and characterization of azole-resistant Aspergillus fumigatus in patients with cystic fibrosis: a prospective multicentre study in Germany.
    J Antimicrob Chemother. 2018 Apr 19. pii: 4978322. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. HAGER CL, Larkin EL, Long LA, Ghannoum MA, et al
    Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model.
    J Antimicrob Chemother. 2018 Apr 19. pii: 4979534. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. RIZZATO C, Poma N, Zoppo M, Posteraro B, et al
    CoERG11 A395T mutation confers azole resistance in Candida orthopsilosis clinical isolates.
    J Antimicrob Chemother. 2018 Apr 9. pii: 4964989. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. ARGUDIN MA, Dodemont M, Taguemount M, Roisin S, et al
    In vitro activity of ceftaroline against clinical Staphylococcus aureus isolates collected during a national survey conducted in Belgian hospitals.
    J Antimicrob Chemother. 2018 Apr 5. pii: 4962127. doi: 10.1093.
    PubMed     Text format    


  11. HASHEMI MM, Rovig J, Holden BS, Taylor MF, et al
    Ceragenins are active against drug-resistant Candida auris clinical isolates in planktonic and biofilm forms.
    J Antimicrob Chemother. 2018 Apr 4. pii: 4960903. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  12. CANEZIN PH, Caleffi-Ferracioli KR, Scodro RBL, Siqueira VLD, et al
    Intramacrophage Mycobacterium tuberculosis efflux pump gene regulation after rifampicin and verapamil exposure.
    J Antimicrob Chemother. 2018 Mar 22. pii: 4951545. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. VAN HAL SJ, Beukers AG, Timms VJ, Ellem JA, et al
    Relentless spread and adaptation of non-typeable vanA vancomycin-resistant Enterococcus faecium: a genome-wide investigation.
    J Antimicrob Chemother. 2018 Mar 16. pii: 4939528. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. DALL GF, Tsang SJ, Gwynne PJ, MacKenzie SP, et al
    Unexpected synergistic and antagonistic antibiotic activity against Staphylococcus biofilms.
    J Antimicrob Chemother. 2018 Mar 14. pii: 4937886. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. CARTER GP, Harjani JR, Li L, Pitcher NP, et al
    1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium.
    J Antimicrob Chemother. 2018 Mar 6. pii: 4922693. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  16. THIEME L, Klinger-Strobel M, Hartung A, Stein C, et al
    In vitro synergism and anti-biofilm activity of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis.
    J Antimicrob Chemother. 2018 Feb 28. pii: 4913717. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. MCCARTY TP, Lockhart SR, Moser SA, Whiddon J, et al
    Echinocandin resistance among Candida isolates at an academic medical centre 2005-15: analysis of trends and outcomes.
    J Antimicrob Chemother. 2018 Feb 28. pii: 4913721. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. RODRIGUEZ-CASTRO E, Trastoy R, Rodriguez-Osorio X, Dominguez-Santalla MJ, et al
    Meningitis due to autochthonous acute infection with hepatitis E virus in a chef: a case report.
    J Antimicrob Chemother. 2018 Feb 21. pii: 4898172. doi: 10.1093.
    PubMed     Text format    


  19. LEBRETON F, Valentino MD, Schaufler K, Earl AM, et al
    Transferable vancomycin resistance in clade B commensal-type Enterococcus faecium.
    J Antimicrob Chemother. 2018 Feb 14. pii: 4859672. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. WESSELS C, Strommenger B, Klare I, Bender J, et al
    Emergence and control of linezolid-resistant Staphylococcus epidermidis in an ICU of a German hospital.
    J Antimicrob Chemother. 2018 Feb 9. pii: 4847818. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. KAMBAREV S, Pecorari F, Corvec S
    Novel Tn916-like elements confer aminoglycoside/macrolide co-resistance in clinical isolates of Streptococcus gallolyticus ssp. gallolyticus.
    J Antimicrob Chemother. 2018 Feb 9. pii: 4847819. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. SUN C, Zhang P, Ji X, Fan R, et al
    Presence and molecular characteristics of oxazolidinone resistance in staphylococci from household animals in rural China.
    J Antimicrob Chemother. 2018 Feb 7. pii: 4841776. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. HUH HJ, Song DJ, Shim HJ, Kwon WK, et al
    Performance evaluation of the QMAC-dRAST for staphylococci and enterococci isolated from blood culture: a comparative study of performance with the VITEK-2 system.
    J Antimicrob Chemother. 2018 Feb 3. pii: 4837262. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. NEVES FPG, Cardoso NT, Souza ARV, Snyder RE, et al
    Population structure of Streptococcus pneumoniae colonizing children before and after universal use of pneumococcal conjugate vaccines in Brazil: emergence and expansion of the MDR serotype 6C-CC386 lineage.
    J Antimicrob Chemother. 2018 Feb 1. pii: 4833983. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  25. LESTRADE PP, van der Velden WJFM, Bouwman F, Stoop FJ, et al
    Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study.
    J Antimicrob Chemother. 2018 Jan 31. pii: 4831957. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. DOOKIE N, Rambaran S, Padayatchi N, Mahomed S, et al
    Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.
    J Antimicrob Chemother. 2018 Jan 19. pii: 4817621. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. LAYER F, Vourli S, Karavasilis V, Strommenger B, et al
    Dissemination of linezolid-dependent, linezolid-resistant Staphylococcus epidermidis clinical isolates belonging to CC5 in German hospitals.
    J Antimicrob Chemother. 2018 Jan 19. pii: 4817623. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. SASSI M, Guerin F, Lesec L, Isnard C, et al
    Genetic characterization of a VanG-type vancomycin-resistant Enterococcus faecium clinical isolate.
    J Antimicrob Chemother. 2018 Jan 16. pii: 4812002. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. REISSIER S, Saleh-Mghir A, Guerin F, Massias L, et al
    In vivo daptomycin efficacy against experimental vancomycin-resistant Enterococcus faecium endocarditis.
    J Antimicrob Chemother. 2018 Jan 9. pii: 4796903. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. CHOWDHARY A, Prakash A, Sharma C, Kordalewska M, et al
    A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance.
    J Antimicrob Chemother. 2018 Jan 9. pii: 4794718. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  31. VAN DEN BUNT G, Top J, Hordijk J, de Greeff SC, et al
    Intestinal carriage of ampicillin- and vancomycin-resistant Enterococcus faecium in humans, dogs and cats in the Netherlands.
    J Antimicrob Chemother. 2017 Dec 25. pii: 4774625. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. EDSLEV SM, Clausen ML, Agner T, Stegger M, et al
    Genomic analysis reveals different mechanisms of fusidic acid resistance in Staphylococcus aureus from Danish atopic dermatitis patients.
    J Antimicrob Chemother. 2017 Dec 14. pii: 4745837. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. LIU Y, Pertinez H, Ortega-Muro F, Alameda-Martin L, et al
    Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
    J Antimicrob Chemother. 2017 Dec 12. pii: 4735127. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. CHEN C, Hooper DC
    Effect of Staphylococcus aureus Tet38 native efflux pump on in vivo response to tetracycline in a murine subcutaneous abscess model.
    J Antimicrob Chemother. 2017 Dec 5. pii: 4693732. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. ZHANG P, Wright JA, Tymon A, Nair SP, et al
    Bicarbonate induces high-level resistance to the human antimicrobial peptide LL-37 in Staphylococcus aureus small colony variants.
    J Antimicrob Chemother. 2017 Dec 4. pii: 4688916. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  36. PITT R, Alexander S, Ison C, Horner P, et al
    Phenotypic antimicrobial susceptibility testing of Chlamydia trachomatis isolates from patients with persistent or successfully treated infections.
    J Antimicrob Chemother. 2017 Nov 30. pii: 4682922. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. KONTOYIANNIS DP, Selleslag D, Mullane K, Cornely OA, et al
    Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial.
    J Antimicrob Chemother. 2017 Nov 29. pii: 4675068. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. WIEDERHOLD NP, Patterson HP, Tran BH, Yates CM, et al
    Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus.
    J Antimicrob Chemother. 2017 Nov 27. pii: 4669681. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. HOMBACH M, Jetter M, Blochliger N, Kolesnik-Goldmann N, et al
    Rapid disc diffusion antibiotic susceptibility testing for Pseudomonas aeruginosa, Acinetobacter baumannii and Enterococcus spp.
    J Antimicrob Chemother. 2017 Nov 23. pii: 4654829. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. WIEDERHOLD NP, Najvar LK, Jaramillo R, Olivo M, et al
    Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata.
    J Antimicrob Chemother. 2017 Nov 21. pii: 4644442. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. FREITAS AR, Tedim AP, Novais C, Coque TM, et al
    Distribution of putative virulence markers in Enterococcus faecium: towards a safety profile review.
    J Antimicrob Chemother. 2017 Nov 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. COSTA SS, Viveiros M, Pomba C, Couto I, et al
    Active antimicrobial efflux in Staphylococcus epidermidis: building up of resistance to fluoroquinolones and biocides in a major opportunistic pathogen.
    J Antimicrob Chemother. 2017 Nov 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. GODET C, Alastruey-Izquierdo A, Flick H, Hennequin C, et al
    A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention.
    J Antimicrob Chemother. 2017 Nov 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. BUIL JB, Bruggemann RJM, Wasmann RE, Zoll J, et al
    Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.
    J Antimicrob Chemother. 2017 Nov 3. doi: 10.1093.
    PubMed     Text format    


    October 2017
  45. DORTET L, Glaser P, Kassis-Chikhani N, Girlich D, et al
    Long-lasting successful dissemination of resistance to oxazolidinones in MDR Staphylococcus epidermidis clinical isolates in a tertiary care hospital in France.
    J Antimicrob Chemother. 2017 Oct 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. VYAZOVAYA A, Levina K, Zhuravlev V, Viiklepp P, et al
    Emerging resistant clones of Mycobacterium tuberculosis in a spatiotemporal context.
    J Antimicrob Chemother. 2017 Oct 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. FOSCHI C, Salvo M, Cevenini R, Marangoni A, et al
    Chlamydia trachomatis antimicrobial susceptibility in colorectal and endocervical cells.
    J Antimicrob Chemother. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. CHEN CJ, Lauderdale TY, Lu CT, Chuang YY, et al
    Clinical and molecular features of MDR livestock-associated MRSA ST9 with staphylococcal cassette chromosome mecXII in humans.
    J Antimicrob Chemother. 2017 Oct 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. BUIL JB, Bruggemann RJM, Wasmann RE, Zoll J, et al
    Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.
    J Antimicrob Chemother. 2017 Oct 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. SEAS C, Garcia C, Salles MJ, Labarca J, et al
    Staphylococcus aureus bloodstream infections in Latin America: results of a multinational prospective cohort study.
    J Antimicrob Chemother. 2017 Oct 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. BREAK TJ, Desai JV, Natarajan M, Ferre EMN, et al
    VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans.
    J Antimicrob Chemother. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  52. HOLYK A, Belden V, Lee JJ, Musick W, et al
    Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report.
    J Antimicrob Chemother. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format    


  53. ARENDRUP MC, Verweij PE, Mouton JW, Lagrou K, et al
    Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus.
    J Antimicrob Chemother. 2017 Oct 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  54. YEW WW, Liang D, Chan DP, Shi W, et al
    Molecular mechanisms of clofazimine resistance in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2017;72:2943-2944.
    PubMed     Text format    


  55. SINGH R, Almutairi M, Alm RA, Lahiri SD, et al
    Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
    J Antimicrob Chemother. 2017;72:2796-2803.
    PubMed     Text format     Abstract available


  56. SCORNEC H, Bellanger X, Guilloteau H, Groshenry G, et al
    Inducibility of Tn916 conjugative transfer in Enterococcus faecalis by subinhibitory concentrations of ribosome-targeting antibiotics.
    J Antimicrob Chemother. 2017;72:2722-2728.
    PubMed     Text format     Abstract available


  57. DOUMITH M, Mushtaq S, Martin V, Chaudhry A, et al
    Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance.
    J Antimicrob Chemother. 2017;72:2704-2707.
    PubMed     Text format     Abstract available


  58. ZHANG Y, Kashikar A, Bush K
    In vitro activity of plazomicin against beta-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
    J Antimicrob Chemother. 2017;72:2792-2795.
    PubMed     Text format     Abstract available


  59. BRENNAN-KROHN T, Truelson KA, Smith KP, Kirby JE, et al
    Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology.
    J Antimicrob Chemother. 2017;72:2775-2781.
    PubMed     Text format     Abstract available


    September 2017
  60. FREITAS AR, Elghaieb H, Leon-Sampedro R, Abbassi MS, et al
    Detection of optrA in the African continent (Tunisia) within a mosaic Enterococcus faecalis plasmid from urban wastewaters.
    J Antimicrob Chemother. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  61. CHEN J, Zhang S, Cui P, Shi W, et al
    Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2017 Sep 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  62. WU CJ, Lai JF, Huang IW, Hsieh LY, et al
    Multiclonal emergence of levofloxacin-resistant group B Streptococcus, Taiwan.
    J Antimicrob Chemother. 2017 Sep 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  63. BELFIELD K, Bayston R, Hajduk N, Levell G, et al
    Evaluation of combinations of putative anti-biofilm agents and antibiotics to eradicate biofilms of Staphylococcus aureus and Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2017;72:2531-2538.
    PubMed     Text format     Abstract available


  64. LEE GC, Dallas SD, Wang Y, Olsen RJ, et al
    Emerging multidrug resistance in community-associated Staphylococcus aureus involved in skin and soft tissue infections and nasal colonization.
    J Antimicrob Chemother. 2017;72:2461-2468.
    PubMed     Text format     Abstract available


  65. PASIPANODYA JG, Ogbonna D, Deshpande D, Srivastava S, et al
    Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  66. DESHPANDE D, Srivastava S, Gumbo T
    A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  67. DESHPANDE D, Srivastava S, Pasipanodya JG, Lee PS, et al
    A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  68. DESHPANDE D, Srivastava S, Pasipanodya JG, Lee PS, et al
    Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  69. DESHPANDE D, Srivastava S, Pasipanodya JG, Gumbo T, et al
    Linezolid as treatment for pulmonary Mycobacterium avium disease.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  70. SRIVASTAVA S, Deshpande D, Gumbo T
    Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


    August 2017
  71. LAZARIS A, Coleman DC, Kearns AM, Pichon B, et al
    Novel multiresistance cfr plasmids in linezolid-resistant methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium (VRE) from a hospital outbreak: co-location of cfr and optrA in VRE.
    J Antimicrob Chemother. 2017 Aug 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  72. CHANG SC, Lee MH, Yeh CF, Liu TP, et al
    Characterization of two novel variants of staphylococcal cassette chromosome mec elements in oxacillin-resistant Staphylococcus lugdunensis.
    J Antimicrob Chemother. 2017 Aug 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  73. GONZALEZ MORENO M, Trampuz A, Di Luca M
    Synergistic antibiotic activity against planktonic and biofilm-embedded Streptococcus agalactiae, Streptococcus pyogenes and Streptococcus oralis.
    J Antimicrob Chemother. 2017 Aug 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  74. SINGH AK, Thakare R, Karaulia P, Das S, et al
    Biological evaluation of diphenyleneiodonium chloride (DPIC) as a potential drug candidate for treatment of non-tuberculous mycobacterial infections.
    J Antimicrob Chemother. 2017 Aug 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  75. SCHAUWVLIEGHE AFAD, Vonk AG, Buddingh EP, Hoek RAS, et al
    Detection of azole-susceptible and azole-resistant Aspergillus coinfection by cyp51A PCR amplicon melting curve analysis.
    J Antimicrob Chemother. 2017 Aug 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  76. WEBER RE, Layer F, Klare I, Werner G, et al
    Comparative evaluation of VITEK(R) 2 and three commercial gradient strip assays for daptomycin susceptibility testing of Staphylococcus aureus.
    J Antimicrob Chemother. 2017 Aug 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  77. COJUTTI PG, Candoni A, Ramos-Martin V, Lazzarotto D, et al
    Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies.
    J Antimicrob Chemother. 2017;72:2342-2350.
    PubMed     Text format     Abstract available


  78. CORNELY OA, Leguay T, Maertens J, Vehreschild MJGT, et al
    Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.
    J Antimicrob Chemother. 2017;72:2359-2367.
    PubMed     Text format     Abstract available


  79. TAUBERT M, Zander J, Frechen S, Scharf C, et al
    Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens.
    J Antimicrob Chemother. 2017;72:2304-2310.
    PubMed     Text format     Abstract available


  80. BEVAN ER, Jones AM, Hawkey PM
    Global epidemiology of CTX-M beta-lactamases: temporal and geographical shifts in genotype.
    J Antimicrob Chemother. 2017;72:2145-2155.
    PubMed     Text format     Abstract available


  81. AYDIN S, Personne Y, Newire E, Laverick R, et al
    Presence of Type I-F CRISPR/Cas systems is associated with antimicrobial susceptibility in Escherichia coli.
    J Antimicrob Chemother. 2017;72:2213-2218.
    PubMed     Text format     Abstract available


  82. MATSUMURA Y, Peirano G, Devinney R, Bradford PA, et al
    Genomic epidemiology of global VIM-producing Enterobacteriaceae.
    J Antimicrob Chemother. 2017;72:2249-2258.
    PubMed     Text format     Abstract available


  83. SVENSSON RJ, Gillespie SH, Simonsson USH
    Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.
    J Antimicrob Chemother. 2017;72:2311-2319.
    PubMed     Text format     Abstract available


  84. LIVERMORE DM, Mushtaq S, Meunier D, Hopkins KL, et al
    Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.
    J Antimicrob Chemother. 2017;72:2278-2289.
    PubMed     Text format     Abstract available


  85. BOTELHO J, Grosso F, Quinteira S, Mabrouk A, et al
    The complete nucleotide sequence of an IncP-2 megaplasmid unveils a mosaic architecture comprising a putative novel blaVIM-2-harbouring transposon in Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2017;72:2225-2229.
    PubMed     Text format     Abstract available


  86. LAGACE-WIENS PRS, Adam HJ, Laing NM, Baxter MR, et al
    Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential.
    J Antimicrob Chemother. 2017;72:2273-2277.
    PubMed     Text format     Abstract available


  87. CHATTERJEE S, Mondal A, Mitra S, Basu S, et al
    Acinetobacter baumannii transfers the blaNDM-1 gene via outer membrane vesicles.
    J Antimicrob Chemother. 2017;72:2201-2207.
    PubMed     Text format     Abstract available


  88. VARGAS-PALACIOS A, Meads DM, Twiddy M, Czoski Murray C, et al
    Cost-effectiveness of outpatient parenteral antibiotic therapy: a simulation modelling approach.
    J Antimicrob Chemother. 2017;72:2392-2400.
    PubMed     Text format     Abstract available


  89. SMITH NM, Bulman ZP, Sieron AO, Bulitta JB, et al
    Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli.
    J Antimicrob Chemother. 2017;72:2297-2303.
    PubMed     Text format     Abstract available


  90. DOUMITH M, Findlay J, Hirani H, Hopkins KL, et al
    Major role of pKpQIL-like plasmids in the early dissemination of KPC-type carbapenemases in the UK.
    J Antimicrob Chemother. 2017;72:2241-2248.
    PubMed     Text format     Abstract available


    July 2017
  91. FIRSOV AA, Alieva KN, Strukova EN, Golikova MV, et al
    Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model.
    J Antimicrob Chemother. 2017 Jul 31. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2017
  92. DI SANTE L, Morroni G, Brenciani A, Vignaroli C, et al
    pHTbeta-promoted mobilization of non-conjugative resistance plasmids from Enterococcus faecium to Enterococcus faecalis.
    J Antimicrob Chemother. 2017 Jun 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  93. BUIL JB, Rijs AJMM, Meis JF, Birch M, et al
    In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
    J Antimicrob Chemother. 2017 Jun 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  94. HURST SF, Berkow EL, Stevenson KL, Litvintseva AP, et al
    Isolation of azole-resistant Aspergillus fumigatus from the environment in the south-eastern USA.
    J Antimicrob Chemother. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


  95. KAUSHIK A, Ammerman NC, Tasneen R, Story-Roller E, et al
    In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  96. HAMMERUM AM, Baig S, Kamel Y, Roer L, et al
    Emergence of vanA Enterococcus faecium in Denmark, 2005-15.
    J Antimicrob Chemother. 2017 May 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  97. MAITRE T, Petitjean G, Chauffour A, Bernard C, et al
    Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?
    J Antimicrob Chemother. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  98. YIM J, Smith JR, Singh NB, Rice S, et al
    Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs).
    J Antimicrob Chemother. 2017 May 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  99. BEN YAAKOV D, Shadkchan Y, Albert N, Kontoyiannis DP, et al
    The quinoline bromoquinol exhibits broad-spectrum antifungal activity and induces oxidative stress and apoptosis in Aspergillus fumigatus.
    J Antimicrob Chemother. 2017 May 5. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2017
  100. ZIMENKOV DV, Nosova EY, Kulagina EV, Antonova OV, et al
    Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
    J Antimicrob Chemother. 2017 Apr 6. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  101. SAN-JUAN R, Fernandez-Ruiz M, Gasch O, Camoez M, et al
    High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus.
    J Antimicrob Chemother. 2017 Mar 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  102. GURUMURTHY M, Verma R, Naftalin CM, Hee KH, et al
    Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial.
    J Antimicrob Chemother. 2017 Mar 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  103. HAWKINS PA, Law CS, Metcalf BJ, Chochua S, et al
    Cross-resistance to lincosamides, streptogramins A and pleuromutilins in Streptococcus agalactiae isolates from the USA.
    J Antimicrob Chemother. 2017 Mar 13. doi: 10.1093.
    PubMed     Text format     Abstract available


  104. JAGANATH D, Schaaf HS, Donald PR
    Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.
    J Antimicrob Chemother. 2017 Mar 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  105. GRONTHAL T, Eklund M, Thomson K, Piiparinen H, et al
    Antimicrobial resistance in Staphylococcus pseudintermedius and the molecular epidemiology of methicillin-resistant S. pseudintermedius in small animals in Finland.
    J Antimicrob Chemother. 2017 Mar 8. doi: 10.1093.
    PubMed     Text format    


  106. DE LASTOURS V, Maugy E, Mathy V, Chau F, et al
    Ecological impact of ciprofloxacin on commensal enterococci in healthy volunteers.
    J Antimicrob Chemother. 2017 Mar 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  107. BLANCHARD AC, Fortin E, Laferriere C, Goyer I, et al
    Comparative effectiveness of linezolid versus vancomycin as definitive antibiotic therapy for heterogeneously resistant vancomycin-intermediate coagulase-negative staphylococcal central-line-associated bloodstream infections in a neonatal intensive ca
    J Antimicrob Chemother. 2017 Mar 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  108. LEDOUX MP, Toussaint E, Denis J, Herbrecht R, et al
    New pharmacological opportunities for the treatment of invasive mould diseases.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  109. BASSETTI M, Bouza E
    Invasive mould infections in the ICU setting: complexities and solutions.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  110. MERCIER T, Maertens J
    Clinical considerations in the early treatment of invasive mould infections and disease.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  111. LAMOTH F, Calandra T
    Early diagnosis of invasive mould infections and disease.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  112. STOTT KE, Hope WW
    Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


  113. LASS-FLORL C, Cuenca-Estrella M
    Changes in the epidemiological landscape of invasive mould infections and disease.
    J Antimicrob Chemother. 2017;72.
    PubMed     Text format     Abstract available


    February 2017
  114. MOUGARI F, Loiseau J, Veziris N, Bernard C, et al
    Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria.
    J Antimicrob Chemother. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  115. CAVANAUGH JS, Jou R, Wu MH, Dalton T, et al
    Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
    J Antimicrob Chemother. 2017 Feb 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  116. RUDRAMURTHY SM, Chakrabarti A, Paul RA, Sood P, et al
    Candida auris candidaemia in Indian ICUs: analysis of risk factors.
    J Antimicrob Chemother. 2017 Feb 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  117. PERICAS JM, Garcia-de-la-Maria C, Brunet M, Armero Y, et al
    Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.
    J Antimicrob Chemother. 2017 Feb 14. doi: 10.1093.
    PubMed     Text format    


  118. MARCOS-ZAMBRANO LJ, Gomez-Perosanz M, Escribano P, Bouza E, et al
    The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.
    J Antimicrob Chemother. 2017 Feb 8. doi: 10.1093.
    PubMed     Text format    


  119. BOIKOV DA, Locke JB, James KD, Bartizal K, et al
    In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis.
    J Antimicrob Chemother. 2017 Feb 3. doi: 10.1093.
    PubMed     Text format    


    January 2017
  120. WERTH BJ
    Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.
    J Antimicrob Chemother. 2017 Jan 31. doi: 10.1093.
    PubMed     Text format    


  121. LEDDA A, Price JR, Cole K, Llewelyn MJ, et al
    Re-emergence of methicillin susceptibility in a resistant lineage of Staphylococcus aureus.
    J Antimicrob Chemother. 2017 Jan 20. pii: dkw570. doi: 10.1093.
    PubMed     Text format     Abstract available


  122. LARSEN J, Andersen PS, Winstel V, Peschel A, et al
    Staphylococcus aureus CC395 harbours a novel composite staphylococcal cassette chromosome mec element.
    J Antimicrob Chemother. 2017 Jan 14. pii: dkw544. doi: 10.1093.
    PubMed     Text format     Abstract available


  123. GOTHAM D, Fortunak J, Pozniak A, Khoo S, et al
    Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    J Antimicrob Chemother. 2017 Jan 10. pii: dkw522. doi: 10.1093.
    PubMed     Text format     Abstract available


  124. HOMBACH M, Weissert C, Senn MM, Zbinden R, et al
    Comparison of phenotypic methods for the detection of penicillinase in Staphylococcus aureus and proposal of a practical diagnostic approach.
    J Antimicrob Chemother. 2017 Jan 8. pii: dkw521. doi: 10.1093.
    PubMed     Text format     Abstract available


  125. XISTO MI, Caramalho RD, Rocha DA, Ferreira-Pereira A, et al
    Pan-azole-resistant Candida tropicalis carrying homozygous erg11 mutations at position K143R: a new emerging superbug?
    J Antimicrob Chemother. 2017 Jan 8. pii: dkw558. doi: 10.1093.
    PubMed     Text format     Abstract available


  126. GRONTHAL T, Eklund M, Thomson K, Piiparinen H, et al
    Antimicrobial resistance in Staphylococcus pseudintermedius and the molecular epidemiology of methicillin-resistant S. pseudintermedius in small animals in Finland.
    J Antimicrob Chemother. 2017 Jan 8. pii: dkw559. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  127. KATRAGKOU A, Williams M, Sternberg S, Pantazatos D, et al
    Micafungin alters the amino acid, nucleic acid and central carbon metabolism of Candida albicans at subinhibitory concentrations: novel insights into mechanisms of action.
    J Antimicrob Chemother. 2016 Dec 30. pii: dkw478. doi: 10.1093.
    PubMed     Text format     Abstract available


  128. ZHU XQ, Wang XM, Li H, Shang YH, et al
    Novel lnu(G) gene conferring resistance to lincomycin by nucleotidylation, located on Tn6260 from Enterococcus faecalis E531.
    J Antimicrob Chemother. 2016 Dec 30. pii: dkw549. doi: 10.1093.
    PubMed     Text format     Abstract available


  129. VAN HAL SJ, Espedido BA, Coombs GW, Howden BP, et al
    Polyclonal emergence of vanA vancomycin-resistant Enterococcus faecium in Australia.
    J Antimicrob Chemother. 2016 Dec 28. pii: dkw539. doi: 10.1093.
    PubMed     Text format     Abstract available


  130. RUPPEN C, Hemphill A, Sendi P
    In vitro activity of gentamicin as an adjunct to penicillin against biofilm group B Streptococcus.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw447. doi: 10.1093.
    PubMed     Text format     Abstract available


  131. ZAPOTOCZNA M, Murray EJ, Hogan S, O'Gara JP, et al
    5-Hydroxyethyl-3-tetradecanoyltetramic acid represents a novel treatment for intravascular catheter infections due to Staphylococcus aureus.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw482. doi: 10.1093.
    PubMed     Text format     Abstract available


  132. BUTIN M, Martins-Simoes P, Pichon B, Leyssene D, et al
    Emergence and dissemination of a linezolid-resistant Staphylococcus capitis clone in Europe.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw516. doi: 10.1093.
    PubMed     Text format     Abstract available


  133. CAVACO LM, Bernal JF, Zankari E, Leon M, et al
    Detection of linezolid resistance due to the optrA gene in Enterococcus faecalis from poultry meat from the American continent (Colombia).
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw490. doi: 10.1093.
    PubMed     Text format     Abstract available


  134. BRITT NS, Patel N, Shireman TI, El Atrouni WI, et al
    Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw453. doi: 10.1093.
    PubMed     Text format     Abstract available


  135. ROBERTSON GT, Scherman MS, Bruhn DF, Liu J, et al
    Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw467. doi: 10.1093.
    PubMed     Text format     Abstract available


  136. YUSTE JR, Berto J, Del Pozo JL, Leiva J, et al
    Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw484. doi: 10.1093.
    PubMed     Text format    


  137. TANIGUCHI R, Kimura K, Miyazaki A, Banno H, et al
    High rate of slowly-killed-by-ampicillin phenotype among group B streptococci with reduced penicillin susceptibility.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw500. doi: 10.1093.
    PubMed     Text format    


    November 2016
  138. SWEENEY D, Stoneburner A, Shinabarger DL, Arhin FF, et al
    Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  139. MAERTENS JA, Blennow O, Duarte RF, Munoz P, et al
    The current management landscape: aspergillosis.
    J Antimicrob Chemother. 2016;71.
    PubMed     Text format     Abstract available


    October 2016
  140. AMMERMAN NC, Swanson RV, Tapley A, Moodley C, et al
    Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  141. CANTON R, Livermore DM, Morosini MI, Diaz-Reganon J, et al
    Etest(R) versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: results from PREMIUM, a European multicentre study.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    September 2016
  142. TEDIM AP, Ruiz-Garbajosa P, Rodriguez MC, Rodriguez-Banos M, et al
    Long-term clonal dynamics of Enterococcus faecium strains causing bloodstream infections (1995-2015) in Spain.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  143. KUBICEK-SUTHERLAND JZ, Lofton H, Vestergaard M, Hjort K, et al
    Antimicrobial peptide exposure selects for Staphylococcus aureus resistance to human defence peptides.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  144. ARGUDIN MA, Dodemont M, Taguemount M, Roisin S, et al
    In vitro activity of ceftaroline against clinical Staphylococcus aureus isolates collected during a national survey conducted in Belgian hospitals.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  145. HOFFMANN H, Borroni E, Schena E, Nedialkova L, et al
    Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system-authors' response.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  146. MORICI E, Simoni S, Brenciani A, Giovanetti E, et al
    A new mosaic integrative and conjugative element from Streptococcus agalactiae carrying resistance genes for chloramphenicol (catQ) and macrolides [mef(I) and erm(TR)].
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  147. MENDES RE, Castanheira M, Farrell DJ, Flamm RK, et al
    Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  148. BERNARD C, Aubry A, Chauffour A, Brossier F, et al
    In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  149. PINHOLT M, Gumpert H, Bayliss S, Nielsen JB, et al
    Genomic analysis of 495 vancomycin-resistant Enterococcus faecium reveals broad dissemination of a vanA plasmid in more than 19 clones from Copenhagen, Denmark.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  150. FUURSTED K, Stegger M, Hoffmann S, Lambertsen L, et al
    Description and characterization of a penicillin-resistant Streptococcus dysgalactiae subsp. equisimilis clone isolated from blood in three epidemiologically linked patients.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    August 2016
  151. WILSON LK, Coombs GW, Christiansen K, Grubb WB, et al
    Characterization of a novel staphylococcal cassette chromosome composite island from community-associated MRSA isolated in aged care facilities in Western Australia.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  152. VALENTIN A, Canton E, Peman J, Fernandez-Rivero ME, et al
    In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  153. FREITAS AR, Tedim AP, Francia MV, Jensen LB, et al
    Multilevel population genetic analysis of vanA and vanB Enterococcus faecium causing nosocomial outbreaks in 27 countries (1986-2012).
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  154. CHONG GM, van der Beek MT, von dem Borne PA, Boelens J, et al
    PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay(R) in 201 patients with haematological disease suspected for invasive aspergillosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  155. IMKAMP F, Keller PM, Bottger EC
    Comment on: Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  156. CARTER GP, Buultjens AH, Ballard SA, Baines SL, et al
    Emergence of endemic MLST non-typeable vancomycin-resistant Enterococcus faecium.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  157. LAHIRI SD, Alm RA
    Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  158. VERWEIJ PE, Lestrade PP, Melchers WJ, Meis JF, et al
    Azole resistance surveillance in Aspergillus fumigatus: beneficial or biased?
    J Antimicrob Chemother. 2016;71:2079-82.
    PubMed     Text format     Abstract available


  159. ALANIO A, Denis B, Hamane S, Raffoux E, et al
    New therapeutic strategies for invasive aspergillosis in the era of azole resistance: how should the prevalence of azole resistance be defined?
    J Antimicrob Chemother. 2016;71:2075-8.
    PubMed     Text format     Abstract available


    July 2016
  160. CHIOTOS K, Vendetti N, Zaoutis TE, Baddley J, et al
    Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  161. SIOPI M, Siafakas N, Vourli S, Mouton JW, et al
    Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  162. THORNLEY T, Marshall G, Howard P, Wilson AP, et al
    A feasibility service evaluation of screening and treatment of group A streptococcal pharyngitis in community pharmacies.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  163. TSAO S, Weber S, Cameron C, Nehme D, et al
    Positive regulation of the Candida albicans multidrug efflux pump Cdr1p function by phosphorylation of its N-terminal extension.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  164. BASAS J, Morer A, Ratia C, Martin MT, et al
    Efficacy of anidulafungin in the treatment of experimental Candida parapsilosis catheter infection using an antifungal-lock technique.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


    June 2016
  165. SINEL C, Cosquer T, Auzou M, Goux D, et al
    Sequential steps of daptomycin resistance in Enterococcus faecium and reversion to hypersusceptibility through IS-mediated inactivation of the liaFSR operon.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  166. CONCEICAO T, de Lencastre H, Aires-de-Sousa M
    Efficacy of octenidine against antibiotic-resistant Staphylococcus aureus epidemic clones.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  167. PFALLER MA, Messer SA, Rhomberg PR, Jones RN, et al
    Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  168. MARTINEZ-JIMENEZ MC, Munoz P, Valerio M, Vena A, et al
    Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  169. EILERTSON B, Maruri F, Blackman A, Guo Y, et al
    A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  170. SABIROVA JS, Xavier BB, Coppens J, Zarkotou O, et al
    Whole-genome typing and characterization of blaVIM19-harbouring ST383 Klebsiella pneumoniae by PFGE, whole-genome mapping and WGS.
    J Antimicrob Chemother. 2016;71:1501-9.
    PubMed     Text format     Abstract available


  171. WIENER-WELL Y, Raveh-Brawer D, Fraenkel-Wandel Y, Yinnon AM, et al
    Mortality due to blaKPC Klebsiella pneumoniae bacteraemia-authors' response.
    J Antimicrob Chemother. 2016;71:1744.
    PubMed     Text format    


  172. GIACOBBE DR, Tumbarello M, Del Bono V, Viscoli C, et al
    Comment on: Mortality due to blaKPC Klebsiella pneumoniae bacteraemia.
    J Antimicrob Chemother. 2016;71:1743-4.
    PubMed     Text format    


  173. HAENNI M, Saras E, Ponsin C, Dahmen S, et al
    High prevalence of international ESBL CTX-M-15-producing Enterobacter cloacae ST114 clone in animals.
    J Antimicrob Chemother. 2016;71:1497-500.
    PubMed     Text format     Abstract available


  174. FERNANDEZ J, Poirel L, Rodicio MR, Nordmann P, et al
    Concomitant and multiclonal dissemination of OXA-48-producing Klebsiella pneumoniae in a Spanish hospital.
    J Antimicrob Chemother. 2016;71:1734-6.
    PubMed     Text format    


    May 2016
  175. PANTEL A, Petrella S, Veziris N, Matrat S, et al
    Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  176. BARCHIESI F, Santinelli A, Biscotti T, Greganti G, et al
    Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  177. NILSEN E, Aasterod M, Hustad PS, Olsen AO, et al
    Mecillinam against genital Chlamydia trachomatis infection: a small-scale proof-of-concept study shows a low cure rate.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  178. LIU P, Xue H, Wu Z, Ma J, et al
    Effect of bla regulators on the susceptible phenotype and phenotypic conversion for oxacillin-susceptible mecA-positive staphylococcal isolates.
    J Antimicrob Chemother. 2016.
    PubMed     Text format     Abstract available


  179. VAN PH, Binh PT, Minh NH, Morrissey I, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 in Vietnam.
    J Antimicrob Chemother. 2016;71 Suppl 1:i93-i102.
    PubMed     Text format     Abstract available


  180. TORUMKUNEY D, Gur D, Soyletir G, Gurler N, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2002-09 in Turkey.
    J Antimicrob Chemother. 2016;71 Suppl 1:i85-i91.
    PubMed     Text format     Abstract available


  181. SOYLETIR G, Altinkanat G, Gur D, Altun B, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in Turkey.
    J Antimicrob Chemother. 2016;71 Suppl 1:i71-i83.
    PubMed     Text format     Abstract available


  182. FESHCHENKO Y, Dzyublik A, Pertseva T, Bratus E, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in Ukraine.
    J Antimicrob Chemother. 2016;71 Suppl 1:i63-i69.
    PubMed     Text format     Abstract available


  183. JAMSHEER A, Rafay AM, Daoud Z, Morrissey I, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in the Gulf States.
    J Antimicrob Chemother. 2016;71 Suppl 1:i45-i61.
    PubMed     Text format     Abstract available


  184. HU F, Zhu D, Wang F, Morrissey I, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 and 2013-14 in China.
    J Antimicrob Chemother. 2016;71 Suppl 1:i33-i43.
    PubMed     Text format     Abstract available


  185. TORUMKUNEY D, Chaiwarith R, Reechaipichitkul W, Malatham K, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2012-14 in Thailand, India, South Korea and Singapore.
    J Antimicrob Chemother. 2016;71 Suppl 1:i3-i19.
    PubMed     Text format     Abstract available


  186. KACOU-NDOUBA A, Revathi G, Mwathi P, Seck A, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2011-14 in the Democratic Republic of Congo, Ivory Coast, Republic of Senegal and Kenya.
    J Antimicrob Chemother. 2016;71 Suppl 1:i21-i31.
    PubMed     Text format     Abstract available


  187. ENNE VI, Johnson AP, Perry JD
    Preface.
    J Antimicrob Chemother. 2016;71 Suppl 1:i1.
    PubMed     Text format    


  188. TORNERO E, Morata L, Martinez-Pastor JC, Angulo S, et al
    Importance of selection and duration of antibiotic regimen in prosthetic joint infections treated with debridement and implant retention.
    J Antimicrob Chemother. 2016;71:1395-401.
    PubMed     Text format     Abstract available


  189. REIGADAS E, Alcala L, Valerio M, Marin M, et al
    Toxin B PCR cycle threshold as a predictor of poor outcome of Clostridium difficile infection: a derivation and validation cohort study.
    J Antimicrob Chemother. 2016;71:1380-5.
    PubMed     Text format     Abstract available


  190. VAN DEN ABEELE AM, Vogelaers D, Vanlaere E, Houf K, et al
    Antimicrobial susceptibility testing of Arcobacter butzleri and Arcobacter cryaerophilus strains isolated from Belgian patients.
    J Antimicrob Chemother. 2016;71:1241-4.
    PubMed     Text format     Abstract available


  191. LINKEVICIUS M, Anderssen JM, Sandegren L, Andersson DI, et al
    Fitness of Escherichia coli mutants with reduced susceptibility to tigecycline.
    J Antimicrob Chemother. 2016;71:1307-13.
    PubMed     Text format     Abstract available


  192. FINDLAY J, Hopkins KL, Doumith M, Meunier D, et al
    KPC enzymes in the UK: an analysis of the first 160 cases outside the North-West region.
    J Antimicrob Chemother. 2016;71:1199-206.
    PubMed     Text format     Abstract available


  193. BOWKER KE, Noel AR, Tomaselli S, MacGowan AP, et al
    Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.
    J Antimicrob Chemother. 2016;71:1270-8.
    PubMed     Text format     Abstract available


  194. KUMARASWAMY M, Lin L, Olson J, Sun CF, et al
    Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia.
    J Antimicrob Chemother. 2016;71:1264-9.
    PubMed     Text format     Abstract available


  195. MOORE JH 2ND, van Opstal E, Kolling GL, Shin JH, et al
    Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model.
    J Antimicrob Chemother. 2016;71:1300-6.
    PubMed     Text format     Abstract available


  196. JOST C, Bidet P, Carrere T, Mariani-Kurkdjian P, et al
    Susceptibility of enterohaemorrhagic Escherichia coli to azithromycin in France and analysis of resistance mechanisms.
    J Antimicrob Chemother. 2016;71:1183-7.
    PubMed     Text format     Abstract available


  197. COJUTTI P, Duranti S, Isola M, Baraldo M, et al
    Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?
    J Antimicrob Chemother. 2016;71:1323-9.
    PubMed     Text format     Abstract available


  198. BRASSEUR A, Hites M, Roisin S, Cotton F, et al
    A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study.
    J Antimicrob Chemother. 2016;71:1386-94.
    PubMed     Text format     Abstract available


  199. MUJAL A, Sola J, Hernandez M, Villarino MA, et al
    Safety and effectiveness of outpatient parenteral antimicrobial therapy in older people.
    J Antimicrob Chemother. 2016;71:1402-7.
    PubMed     Text format     Abstract available


  200. GLUPCZYNSKI Y, Evrard S, Ote I, Mertens P, et al
    Evaluation of two new commercial immunochromatographic assays for the rapid detection of OXA-48 and KPC carbapenemases from cultured bacteria.
    J Antimicrob Chemother. 2016;71:1217-22.
    PubMed     Text format     Abstract available


  201. MURATA S, Mushino T, Hosoi H, Kuriyama K, et al
    Extracorporeal antimicrobial elimination enables antimicrobial mixing and affects resident bacteria.
    J Antimicrob Chemother. 2016;71:1430-2.
    PubMed     Text format    


  202. BATHOORN E, Tsioutis C, da Silva Voorham JM, Scoulica EV, et al
    Emergence of pan-resistance in KPC-2 carbapenemase-producing Klebsiella pneumoniae in Crete, Greece: a close call.
    J Antimicrob Chemother. 2016;71:1207-12.
    PubMed     Text format     Abstract available


  203. KOSTYANEV T, Strateva T, Xavier BB, Marteva-Proevska Y, et al
    Detection and characterization of two NDM-1-producing Klebsiella pneumoniae strains from Bulgaria.
    J Antimicrob Chemother. 2016;71:1428-30.
    PubMed     Text format    


  204. DAY MJ, Rodriguez I, van Essen-Zandbergen A, Dierikx C, et al
    Diversity of STs, plasmids and ESBL genes among Escherichia coli from humans, animals and food in Germany, the Netherlands and the UK.
    J Antimicrob Chemother. 2016;71:1178-82.
    PubMed     Text format     Abstract available


  205. KIM JC, Jeon B
    Novel adjuvant strategy to potentiate bacitracin against MDR MRSA.
    J Antimicrob Chemother. 2016;71:1260-3.
    PubMed     Text format     Abstract available


  206. MILLAR MR, Seale J, Turton J, Wilks M, et al
    ESBL-producing Enterobacteriaceae in 24 neonatal units and associated networks in the south of England: no clustering of ESBL-producing Escherichia coli in units or networks.
    J Antimicrob Chemother. 2016;71:1174-7.
    PubMed     Text format     Abstract available


    March 2016
  207. HAMIDIAN M, Hall RM
    The resistance gene complement of D4, a multiply antibiotic-resistant ST25 Acinetobacter baumannii isolate, resides in two genomic islands and a plasmid.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  208. FINCH R
    Professor Francis William O'Grady, 7 November 1925-20 May 2015.
    J Antimicrob Chemother. 2016;71:567-8.
    PubMed     Text format    


  209. KAMESHWAR K, Karahalios A, Janus E, Karunajeewa H, et al
    False economies in home-based parenteral antibiotic treatment: a health-economic case study of management of lower-limb cellulitis in Australia.
    J Antimicrob Chemother. 2016;71:830-5.
    PubMed     Text format     Abstract available


  210. THOMPSON CN, Thieu NT, Vinh PV, Duc AN, et al
    Clinical implications of reduced susceptibility to fluoroquinolones in paediatric Shigella sonnei and Shigella flexneri infections.
    J Antimicrob Chemother. 2016;71:807-15.
    PubMed     Text format     Abstract available


  211. CAMPOS J, Mourao J, Marcal S, Machado J, et al
    Clinical Salmonella Typhimurium ST34 with metal tolerance genes and an IncHI2 plasmid carrying oqxAB-aac(6')-Ib-cr from Europe.
    J Antimicrob Chemother. 2016;71:843-5.
    PubMed     Text format    


  212. KINGSLEY J, Mehra P, Lawrence LE, Henry E, et al
    A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin.
    J Antimicrob Chemother. 2016;71:821-9.
    PubMed     Text format     Abstract available


  213. SAKTIAWATI AM, Sturkenboom MG, Stienstra Y, Subronto YW, et al
    Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.
    J Antimicrob Chemother. 2016;71:703-10.
    PubMed     Text format     Abstract available


  214. RIEU R, Chang C, Collin SM, Fazekas J, et al
    Time to detection in liquid culture of sputum in pulmonary MDR-TB does not predict culture conversion for early discharge.
    J Antimicrob Chemother. 2016;71:803-6.
    PubMed     Text format     Abstract available


  215. VAN DER BIJ AK, Frentz D, Bonten MJ
    Gram-positive cocci in Dutch ICUs with and without selective decontamination of the oropharyngeal and digestive tract: a retrospective database analysis.
    J Antimicrob Chemother. 2016;71:816-20.
    PubMed     Text format     Abstract available


  216. BRUMLEY PE, Malani AN, Kabara JJ, Pisani J, et al
    Effect of an antimicrobial stewardship bundle for patients with Clostridium difficile infection.
    J Antimicrob Chemother. 2016;71:836-40.
    PubMed     Text format     Abstract available


  217. KOMP LINDGREN P, Higgins PG, Seifert H, Cars O, et al
    Prevalence of hypermutators among clinical Acinetobacter baumannii isolates.
    J Antimicrob Chemother. 2016;71:661-5.
    PubMed     Text format     Abstract available


  218. YOON EJ, Goussard S, Nemec A, Lambert T, et al
    Origin in Acinetobacter gyllenbergii and dissemination of aminoglycoside-modifying enzyme AAC(6')-Ih.
    J Antimicrob Chemother. 2016;71:601-6.
    PubMed     Text format     Abstract available


  219. VAN KONINGSBRUGGEN-RIETSCHEL S, Heuer HE, Merkel N, Posselt HG, et al
    Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
    J Antimicrob Chemother. 2016;71:711-7.
    PubMed     Text format     Abstract available


  220. STRUKOVA EN, Portnoy YA, Zinner SH, Firsov AA, et al
    Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
    J Antimicrob Chemother. 2016;71:678-84.
    PubMed     Text format     Abstract available


  221. CORNELY OA, Duarte RF, Haider S, Chandrasekar P, et al
    Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
    J Antimicrob Chemother. 2016;71:718-26.
    PubMed     Text format     Abstract available


  222. FLOREZ-CUADRADO D, Ugarte-Ruiz M, Quesada A, Palomo G, et al
    Description of an erm(B)-carrying Campylobacter coli isolate in Europe.
    J Antimicrob Chemother. 2016;71:841-3.
    PubMed     Text format    


  223. WANG Y, Dong Y, Deng F, Liu D, et al
    Species shift and multidrug resistance of Campylobacter from chicken and swine, China, 2008-14.
    J Antimicrob Chemother. 2016;71:666-9.
    PubMed     Text format     Abstract available


  224. KULLAR R, Sakoulas G, Deresinski S, van Hal SJ, et al
    When sepsis persists: a review of MRSA bacteraemia salvage therapy.
    J Antimicrob Chemother. 2016;71:576-86.
    PubMed     Text format     Abstract available


    January 2016
  225. PFEIFER Y, Hunfeld KP, Borgmann S, Maneg D, et al
    Carbapenem-resistant Acinetobacter baumannii ST78 with OXA-72 carbapenemase and ESBL gene blaCTX-M-115.
    J Antimicrob Chemother. 2016.
    PubMed     Text format    


  226. PAPAREDDY P, Kasetty G, Kalle M, Bhongir RK, et al
    NLF20: an antimicrobial peptide with therapeutic potential against invasive Pseudomonas aeruginosa infection.
    J Antimicrob Chemother. 2016;71:170-80.
    PubMed     Text format     Abstract available


  227. VAN DUIJKEREN E, Hengeveld P, Zomer TP, Landman F, et al
    Transmission of MRSA between humans and animals on duck and turkey farms.
    J Antimicrob Chemother. 2016;71:58-62.
    PubMed     Text format     Abstract available


  228. GOMEZ P, Lozano C, Camacho MC, Lima-Barbero JF, et al
    Detection of MRSA ST3061-t843-mecC and ST398-t011-mecA in white stork nestlings exposed to human residues.
    J Antimicrob Chemother. 2016;71:53-7.
    PubMed     Text format     Abstract available


    November 2015
  229. BIELICKI JA, Sharland M, Johnson AP, Henderson KL, et al
    Selecting appropriate empirical antibiotic regimens for paediatric bloodstream infections: application of a Bayesian decision model to local and pooled antimicrobial resistance surveillance data.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


    October 2015
  230. KARLOWSKY JA, Biedenbach DJ, Bouchillon SK, Iaconis JP, et al
    In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.
    J Antimicrob Chemother. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bacterial Infections and Mycoses is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: